Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Thu Dec 11, 3:05PM CST

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of...

TERN : 41.41 (-0.26%)
Terns Announces Pricing of Upsized $650 Million Public Offering GlobeNewswire - Tue Dec 9, 10:30PM CST

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of...

TERN : 41.41 (-0.26%)
Terns Announces Proposed Public Offering GlobeNewswire - Tue Dec 9, 5:12AM CST

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced...

TERN : 41.41 (-0.26%)
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting GlobeNewswire - Mon Dec 8, 1:45PM CST

64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile...

TERN : 41.41 (-0.26%)
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire - Fri Nov 14, 3:05PM CST

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of...

TERN : 41.41 (-0.26%)
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire - Mon Nov 10, 3:05PM CST

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from...

TERN : 41.41 (-0.26%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Tue Nov 4, 3:05PM CST

FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 41.41 (-0.26%)
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting GlobeNewswire - Mon Nov 3, 8:05AM CST

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host...

TERN : 41.41 (-0.26%)
Doctor holding money by IherPhoto via iStock
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 Barchart - Tue Oct 28, 6:30AM CDT

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

SLN : 6.34 (+2.26%)
CRDL : 0.9600 (-3.33%)
TERN : 41.41 (-0.26%)
INO : 1.76 (-23.14%)
TARA : 5.39 (-2.88%)
ATRA : 17.50 (+1.33%)
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity GlobeNewswire - Tue Oct 21, 3:05PM CDT

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants...

TERN : 41.41 (-0.26%)

Barchart Exclusives

The Top-Performing S&P 500 Stock in 2025 Was This 1 Unexpected Company Barchart - 9 minutes ago
Western Digital is on track to closing this year as the top performing S&P 500 stock – but Morgan Stanley analysts believe WDC shares will push further up in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot